Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
76 hedge funds and large institutions have $286M invested in Avadel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 15 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less funds holding
Funds holding: 87 → 76 (-11)
21% less capital invested
Capital invested by funds: $360M → $286M (-$74M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $86K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.58M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.31M |
| 3 |
AC
Armistice Capital
New York
|
+$2.51M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.23M |
| 5 |
Morgan Stanley
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$10.2M |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$5.46M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$5.04M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$4.96M |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$2.96M |
AVDL Hedge Fund Activity: Q4 2016 in Review
76 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2016, worth a combined $286M — down 21% from $360M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AVDL and 6 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.58M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $10.2M sold.
- 76 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2016, down from 87 in Q3 2016.
- Funds reported $286M of Avadel Pharmaceuticals stock for Q4 2016, down 21% quarter-over-quarter.
- 6 funds opened new Avadel Pharmaceuticals positions in Q4 2016 and 15 closed out, a net change of -9 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2016 was Stonepine Capital Management, an estimated $3.58M added.
- The largest Avadel Pharmaceuticals seller in Q4 2016 was J. Goldman & Co, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2016.